Billie Mitchell, MS, RN, CNS | |
9844 Lori Rd Ste 102, Chesterfield, VA 23832-6691 | |
(804) 553-9702 | |
Not Available |
Full Name | Billie Mitchell |
---|---|
Gender | Female |
Speciality | Clinical Nurse Specialist - Psychiatric/mental Health |
Location | 9844 Lori Rd Ste 102, Chesterfield, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609365592 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
364SP0808X | Clinical Nurse Specialist - Psychiatric/mental Health | 0015000704 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Billie Mitchell, MS, RN, CNS 2300 Ginter St, Henrico, VA 23228-5916 Ph: () - | Billie Mitchell, MS, RN, CNS 9844 Lori Rd Ste 102, Chesterfield, VA 23832-6691 Ph: (804) 553-9702 |
News Archive
Today BioSpace, the leading life sciences employment and news website, launched the 2011-2012 Biotech Beach Hotbed Campaign, marking the 14th edition.
Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA's Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.
In May 2020, a team led by thoracic surgeon Konrad Hoetzenecker of the Department of Surgery of MedUni Vienna and Vienna General Hospital performed a lung transplant on a 44-year-old patient who had been seriously ill with Covid-19, making her the first patient in Europe to receive a lung transplant for this indication.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of ENSPIRIT, a Phase 3 trial evaluating custirsen for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after initial chemotherapy treatment has failed.
› Verified 8 days ago